RenovoRx Operating Income

The latest operating income for RNXT is $-13M as of March 2026. That compares with $-12M in the prior-year period — down 10.9% year over year. Investors often review this figure alongside RenovoRx's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNXT's operating income moved from $-12M to $-13M — a 10.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RenovoRx's operating scale or balance-sheet position.

A operating income figure of $-13M for RNXT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RNXT's operating income ($-13M), review year-over-year change from $-12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.